STAT

DECEMBER 6, 2023

As a teenager, Marie Tornyenu was always having to explain herself. If it wasn’t the chronic absences that had her doing homework from a hospital bed, it was the quilted blanket she carried with her on the days she could attend class. “It was a running joke that I was like 80 years old,” she said. “I would usually just laugh it off because the alternative was too depressing.

Hospitals 361

Hospitals 361

PharmaVoice

DECEMBER 6, 2023

This year’s many firsts included a vaccine for RSV and a drug that slows Alzheimer’s disease.

Vaccines 265

Vaccines 265

STAT

DECEMBER 6, 2023

The New England Journal of Medicine, the world’s oldest continually published medical journal, publicly reckoned with its history and complicity surrounding slavery and racism Wednesday, publishing the first of a series of essays by independent historians on the role the prestigious publication has played in perpetuating racist thinking in medicine that continues to this day.

357

357

Safe Biologics

DECEMBER 6, 2023

ASBM Statement: In Shocking Reversal, CMS Wants to Allow Medicare Part D Plan Sponsors to Substitute Non-Interchangeable Biosimilars On November 6, 2023, the Centers for Medicare and Medicaid Services (CMS) announced a proposed Rule that would permit Medicare Part D plan sponsors to substitute non-interchangeable biosimilars in place of the biologic medicines now used to treat many chronic conditions such as rheumatoid arthritis, Crohn’s disease and cancer.

Biosimilars 130

Biosimilars Packaging Labelling Drug Development 130

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

DECEMBER 6, 2023

A study billed as the last chance to develop an HIV vaccine this decade has been shut down, investigators announced Wednesday at a conference in Harare, Zimbabwe. The trial, known as PrEPVacc, was testing two different vaccine regimens on about 1,500 volunteers in East and Southern Africa. After multiple other high-profile trials failed , a PrEPVacc investigator described the study this summer as “ the last roll of the dice ” for an HIV vaccine until the 2030s.

Vaccines 341

Vaccines Drug Development 341

PharmaVoice

DECEMBER 6, 2023

The gene editing biotech is shelving two of its most advanced cancer drugs, and joining a growing group of companies exploring cell-based medicines for inflammatory diseases like lupus.

130

130

BioPharma Dive

DECEMBER 6, 2023

The deal hands AbbVie a portfolio of psychiatric medicines that originated within Pfizer, among them a closely watched schizophrenia treatment that’s in late-stage testing.

122

122

STAT

DECEMBER 6, 2023

Stephen Hemsley, the board chair and former CEO of UnitedHealth Group, has sold nearly $113 million worth of company stock since the middle of October, new filings show. Hemsley most recently sold $36.4 million worth of stock on Tuesday, according to the documents filed with the Securities and Exchange Commission. The other $76.5 million of UnitedHealth stock was sold in October and November.

Documentation 306

Documentation 306

The Pharmacist

DECEMBER 6, 2023

A general practice on the south coast is using a giant advent calendar in its high-street windows to help patients stay well during the winter. Pharmacist partner in the Brighton Health and Wellbeing Centre Shilpa Patel told The Pharmacist that the self-care display is intended to educate patients, tackle misinformation, and relieve winter pressures on […] The post GP practice launches ‘self-care’ advent calendar to help relieve winter pressures appeared first on The Pharmacist.

118

118

STAT

DECEMBER 6, 2023

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales. CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here.

294

294

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

PharmExec

DECEMBER 6, 2023

Experts from Hootsuite noted that the primary social media ROI concern for healthcare companies is the time and money it takes to maintain a multi-platform presence.

119

119

STAT

DECEMBER 6, 2023

In today’s mostly plague- and famine-free world, if you can avoid more modern scourges like gun and car violence , you can expect your death to arrive not with a bang but a whimper; when one of your organs sput-sput-sputters out. And it is usually just one organ or organ system. For some, it’s a calcium-clogged heart. For others, kidneys that no longer filter.

289

289

The Pharmacist

DECEMBER 6, 2023

We speak to the Pharmacist/Pharmacy Team of the Year Award shortlisted pharmacists ahead of this year’s General Practice Awards, to be held on 8 December in London. The fourth entry under the spotlight from this year’s shortlist of six is the Haringey GP Federation clinical pharmacy team. Among the significant work of the Haringey team […] The post Meet the Pharmacy Team of the Year Award shortlist: Haringey GP Federation clinical pharmacy team appeared first on The Pharmacist.

102

102

STAT

DECEMBER 6, 2023

Ovarian cancer owes its often-dismal prognosis to the late stage at which it’s typically discovered. If a tumor is found when it’s small and cancer cells haven’t spread, treatment works well for 90% of patients. But most women are diagnosed at stage 3 or later in their disease, when only 30% reach the five-year survival benchmark.

288

288

Pharmaceutical Technology

DECEMBER 6, 2023

Seattle Children's launched BrainChild Bio to focus on expediting the development of CAR T-cell therapies in central nervous system tumours.

Hospitals 124

Hospitals 124

STAT

DECEMBER 6, 2023

Abbvie announced Wednesday that it will purchase Cerevel Therapeutics and its pipeline of experimental neurological and psychiatric medications for $8.7 billion. The deal marks the second billion-dollar acquisition by AbbVie in under a week. Facing the prospect of declining sales from two of its best-selling drugs, the company also acquired Immunogen and its ovarian cancer treatment for $10 billion last Thursday.

274

274

The Pharmacist

DECEMBER 6, 2023

NHS England is to review its commissioning recommendations for cardiovascular disease (CVD) after a cheaper direct oral anticoagulant (DOAC) has appeared on the market, Pulse PCN understands. Under the 2022/23 Network DES, NHS England had incentivised PCNs to start prescribing edoxaban to new patients and consider switching patients over, following a procurement deal with the […] The post NHS drug deal to be reviewed after cheaper DOAC released appeared first on The Pharmacist.

106

106

STAT

DECEMBER 6, 2023

With 10 days to go, only one company has responded to a demand by the U.S. Federal Trade Commission for several brand-name drugmakers to delist dozens of patents that were improperly or inaccurately listed in a government registry, according to a source familiar with the matter. As a result, the agency is readying plans to file lawsuits against the other companies, some of which are among the biggest drugmakers in the world, such as AbbVie, AstraZeneca, and GSK.

260

260

Pharma Times

DECEMBER 6, 2023

The neurological condition currently affects one in 300 people in the UK - News - PharmaTimes

145

145

STAT

DECEMBER 6, 2023

In a victory for the pharmaceutical industry, a U.S. judge ruled that Minnesota must temporarily halt a controversial law that is designed to provide transparency into prescription drug pricing over concerns that it is unconstitutional. The order was issued in response to a lawsuit filed last July by the Association for Accessible Medicine, which argued the law gives Minnesota the power to regulate interstate commerce and apply the law to prices charged in other states.

Drug Pricing 254

Drug Pricing Pharmaceutical Manufacturing 254

The Pharmacist

DECEMBER 6, 2023

We speak to the Pharmacist/Pharmacy Team of the Year Award shortlist, ahead of this year’s General Practice Awards that will be held on 8 December in London. The fifth entry under the spotlight from this year’s shortlist of six is the Spring Hill Practice pharmacy team, based in north London. This pharmacy team's collaborative approach […] The post Meet the Pharmacy Team of the Year Award shortlist: Spring Hill Practice pharmacy team appeared first on The Pharmacist.

97

97

STAT

DECEMBER 6, 2023

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Diabetes 252

Diabetes Drug Pricing 252

Med Ed 101

DECEMBER 6, 2023

Patients who live with asthma or COPD often require the use of inhaler(s) to help manage symptoms of their disease. As healthcare professionals we must ensure that the medications these patients are receiving actually work. In this article, we provide a table on inhaler storage and beyond use dates. You’ll find this free inahler storage […] The post Inhaler Storage and Beyond Use Dates Table: Free Downloadable PDF appeared first on Med Ed 101.

105

105

STAT

DECEMBER 6, 2023

Understand how science, health policy, and medicine shape the world everyday. Sign up for our Morning Rounds newsletter here. Good morning. Today Megan Molteni tells us how infertility worries will likely temper sickle cell patients’ embrace of new gene therapies.

Drug Development 182

Drug Development Hospitals 182

BioPharma Dive

DECEMBER 6, 2023

The pharma is developing Fabhalta, now cleared for paroxysmal nocturnal hemoglobinuria, for several other rare, complement-driven diseases.

115

115

STAT

DECEMBER 6, 2023

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Hello, everyone. Damian here with some unrest at well-funded startups, a curious biotech run-up, and long-awaited news at BIO.

Drug Pricing 166

Drug Pricing Drug Development 166

Express Pharma

DECEMBER 6, 2023

AstraZeneca presented new data findings from Phase-III studies of HIMALAYA and MATTERHORN a t the ESMO Asia Congress 2023, The company showcased innovative therapeutic options, particularly in the efficacy of immunotherapy combinations in treating advanced unresectable hepatocellular carcinoma and early gastric cancer. Highlights from the HIMALAYA Phase III trial, show improved meaningful survival with an immunotherapy combination of durvalumab and tremelimumab in advanced and unresectable

Immunity 100

Immunity Immunization Chemotherapy 100

Pharma Times

DECEMBER 6, 2023

The commitments will make health systems faster, simpler and fairer for patients - News - PharmaTimes

123

123

The Thyroid Pharmacist

DECEMBER 6, 2023

What is the right diet to heal Hashimoto’s? I hear this question a lot. Unfortunately, the answer isn’t always straightforward, as nutrition is the only science where multiple answers can be both correct and wrong. One (wo)man’s medicine can be another (wo)man’s poison. It took time, experimentation, and further testing, to finally land on the diet that worked based on my own body’s needs.

Immunity 96

Immunity Immunization Adverse Reactions Packaging 96

Express Pharma

DECEMBER 6, 2023

Venus Remedies has received marketing authorisation for three key drugs from Philippines and Saudi Arabia. Venus Remedies has received regulatory approval from Philippines for chemotherapy drug paclitaxel and zoledronic acid, a medication used to treat metabolic bone disorders. The company has also secured marketing authorisation from Saudi Arabia for another oncology drug, bleomycin.

Chemotherapy 97

Chemotherapy 97

pharmaphorum

DECEMBER 6, 2023

Sanofi has deepened an existing collaboration with artificial intelligence specialist Aqemia in the latest among a flurry of collaborations between pharma companies and generative AI (genAI) companies. The French pharma group has signed a multi-year agreement with Paris-based Aqemia, focused on the discovery of small-molecule drug candidates across multiple therapeutic categories, through the application of genAI and deep physics algorithms that can model molecular interactions.

95

95

PharmExec

DECEMBER 6, 2023

National Library of Medicine study emphasizes inadequacies in ensuring the safety and efficacy of over-the-counter dietary supplements.

105

105

Express Pharma

DECEMBER 6, 2023

Merck recently announced the winners of Merck Young Scientists Awards, Season-3 to recognise young scientists in India. Held at Bangalore, the annual awards recognise the work of young scientists who are driving positive change in the lives of millions across India through their cutting-edge research in life sciences. Reportedly, the third season of the Merck Young Scientist Award Program garnered an overwhelming response with over 1500 registrations from nearly 800 institutes across India, res

91

91

European Pharmaceutical Review

DECEMBER 6, 2023

The US Food and Drug Administration (FDA) has approved the first oral monotherapy treatment for adults with paroxysmal nocturnal haemoglobinuria (PNH). Novartis’ Factor B inhibitor, Fabhalta ® (iptacopan) provides comprehensive control of red blood cell (RBC) destruction, according to the company. Novartis releases data for potentially “practice-changing” PNH medicine Key Phase III data for iptacopan “In clinical studies, iptacopan was superior to anti-C5s in haemoglobin improv

86

86

Pharmaceutical Technology

DECEMBER 6, 2023

IGM will lay off 22% of its staff and suspend four clinical activities to advance autoimmune diseases and colorectal cancer programmes.

98

98